Valion Bio, Inc. — Form 8-K Summary
Reporting date: October 7, 2026 (filed October 8, 2026). The filing reports a financing agreement; it does not provide operating or period financial results.
Business context and transaction
Valion Bio, Inc. (Nasdaq: VBIO) entered into a third side letter with 3i, LP under their Series B Preferred Purchase Agreement. The original agreement, dated April 29, 2025 and assigned and amended December 9, 2025, contemplated purchases in multiple closings of up to $8.4 million in securities.
Under the October 7 side letter, 3i agreed to purchase, and the company agreed to issue, 50 shares of Series B Non-Voting Convertible Preferred Stock and warrants to purchase 1,539 common shares at an initial exercise price of $2.5520 per share, for $50,000. The transaction is subject to conditions that may be satisfied or waived by 3i at closing; the 8-K does not confirm that closing occurred.
Financial metrics and changes
The filing provides no revenue, profit, cash flow, margin, debt, liquidity, or other operating metrics. It describes a $50,000 securities purchase, not financial performance. No comparable-period results are provided. The transaction adds a further proposed issuance under the existing Series B financing arrangement.
Risks and other matters
The securities were to be issued in an unregistered offering under Section 4(a)(2) of the Securities Act and/or Rule 506(b). The company’s forward-looking-statement notice identifies general risks and uncertainties that could cause actual results to differ from expectations; it does not specify transaction-specific contingencies beyond the closing conditions.
Investor verification points
- Confirm whether the closing occurred and whether the stated conditions were satisfied or waived.
- Review Exhibit 10.1 and the full Series B Purchase Agreement for preferred-stock conversion terms, warrant provisions, and remaining financing capacity.
- Assess potential dilution from conversion of the preferred shares and exercise of the warrants, including any applicable adjustments.